- This event has passed.
Uterine Fibroid Management CME
October 1
Uterine Fibroid Management CME
Physicians may earn a maximum of 1.5 AMA PRA Category 1 Credits™
Enduring Module
Launch Date: July 14, 2023
Expiration Date: July 13, 2024
Faculty
- Dr. Cheruba Prabakar, MD OBGYN – Board certified OBGYN & minimally invasive trained surgeon specializing in treating fibroids, Lamorinda Gynecology & Surgery
- Dr. Jessica Ritch, MD OBGYN – board-certified & fellowship-trained in minimally invasive gynecologic surgery, Florida Center for Urogynecology
About this module
- Overview of at-risk population, symptom profile, and current practice guidelines for diagnosis and management of uterine fibroids, compelling need for early diagnosis.
- Review desirable outcomes and need for shared decision-making to achieve patient preferences
- Introduce the estrogen threshold hypothesis and the role of GnRH antagonists as a treatment for uterine fibroids including long-term outcomes
- Patient stories & case studies
- See Patient Story from Tanika Gray Valbrun: “Believing Me When I Say I Struggle with Fibroids”
Continuing Education Information
Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Indiana University School of Medicine and AMWA. Indiana University School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
Indiana University School of Medicine designates this enduring material activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure Summary
Indiana University School of Medicine (IUSM) policy ensures that those who have influenced the content of a CE activity (e.g. planners, faculty, authors, reviewers and others) disclose all financial relationships with any ineligible companies so that IUSM may identify and mitigate any conflicts of interest prior to the activity. All educational programs sponsored by Indiana University School of Medicine must demonstrate balance, independence, objectivity, and scientific rigor.
There are no relevant financial relationship(s) with ineligible companies for anyone who was in control of the content of this activity.
An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
This activity is supported by an educational grant from Pfizer.
